Zoetis Inc.

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
158.4 ^USD	+3.30%		+8.14%	-19.73%

Apr. 23	Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating	MT
Apr. 22	Jefferies Lowers Zoetis Price Target to $200 from $220	MT

Catalent Promotes Executive to Succeed CFO, Who Will Depart for Zoetis

May 11, 2021 at 07:38 am EDT

By Dave Sebastian

Catalent Inc. said it is promoting Thomas Castellano, the company's global vice president of operational finance, to chief financial officer effective June 1, as finance chief Wetteny Joseph is departing for Zoetis Inc.

Mr. Castellano joined the contract drug manufacturer as director for financial planning and analysis in 2008 and played a role in the company's initial public offering in 2014, the company said. He has worked with the capital markets finance group at Lehman Brothers.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

05-11-21 0737ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	DOW JONES INDUSTRIAL	38,240 PTS	+0.40%	+1.23%	-
	CATALENT, INC.	55.92 USD	+0.22%	+0.79%	10.1B

Latest news about Zoetis Inc.

Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating	Apr. 23	MT
Jefferies Lowers Zoetis Price Target to $200 from $220	Apr. 22	MT
Zoetis Signs 12-Year Virtual Power Purchase Agreement With Scout Clean Energy	Apr. 18	MT
Zoetis Inc. Announces Executive Changes	Apr. 16	CI
Piper Sandler Adjusts Zoetis' Price Target to $195 From $220, Maintains Overweight Rating	Apr. 16	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 12	MT
Sector Update: Health Care Stocks Lower Friday Afternoon	Apr. 12	MT
Sector Update: Health Care	Apr. 12	MT
Zoetis Shares Fall After Dog Owners Reportedly Blame Arthritis Drug Librela for Pet Illnesses	Apr. 12	MT
Zoetis Shares Slip Premarket After WSJ Report on Arthritis Drugs for Pets	Apr. 12	DJ
Zoetis Inc Files a Definitive Proxy Statement with Securities and Exchange Commission	Apr. 10	CI
Zoetis Inc: World leader in animal health	Apr. 03
Stifel Cuts Price Target on Zoetis to $195 From $215, Maintains Buy Rating	Apr. 02	MT
Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors	Apr. 01	CI
Zoetis Inc Receives a Shareholder Proposal from John Chevedden	Mar. 27	CI
EU Regulator Initiates Antitrust Probe on US Animal Health Company Zoetis	Mar. 27	MT
European Commission Opens Antitrust Probe Into Zoetis	Mar. 26	MT
EU Opens Antitrust Investigation Into Zoetis	Mar. 26	MT
Zoetis to Be Investigated by EU Over Possible Breach of Competition Rules -- 2nd Update	Mar. 26	DJ
EU to Investigate Zoetis Over Possible Breach of Competition Rules -- Update	Mar. 26	DJ
EU to Investigate Zoetis Over Possible Breach of Competition Rules	Mar. 26	DJ
EU targets Zoetis in antitrust investigation over dog medicines	Mar. 26	RE
Old demons return as tech takes a dive	Mar. 15
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	Mar. 15
Transcript : Zoetis Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:30 AM	Mar. 14

Chart Zoetis Inc.

Duration

Period

More charts

Company Profile

Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Zoetis Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

158.4 USD

Average target price

215.2 USD

Spread / Average Target

+35.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
ZOETIS INC.	-19.73%	70.08B
ELANCO ANIMAL HEALTH INCORPORATED	-11.01%	6.43B
BLUESTAR ADISSEO COMPANY	+15.88%	3.52B
VIRBAC	-2.92%	3.11B
VIMIAN GROUP AB	-0.68%	1.38B
JINYU BIO-TECHNOLOGY CO., LTD.	-17.27%	1.37B
VETOQUINOL SA	-2.73%	1.24B
WUHAN KEQIAN BIOLOGY CO.,LTD	-14.67%	1.13B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-5.37%	1.02B
PULIKE BIOLOGICAL ENGINEERING, INC.	-24.06%	838M

Veterinary Drugs

Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Catalent Promotes Executive to Succeed CFO, Who Will Depart for Zoetis

Stocks mentioned in the article

EPS Revisions